Article

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses

2025-04-17

Abstract excerpt

<title>Abstract</title> <p>Despite the proven clinical activity of checkpoint inhibitors (ICIs) in several cancer indications, frequent occurrence of primary and secondary resistance reduces their overall effectiveness. Development of ICI resistance has been attributed mainly to genetic or epigenic alterations that affect the tumor antigen presentation machinery leading to diminished anti-tumor immune responses....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8ec74876-8466-518b-8a22-7c595b47a07f
DOI: 10.21203/rs.3.rs-6024931/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responsesDOI 10.21203/rs.3.rs-6024931/v1Read

Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.Semantic proximity Read

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast CancersSemantic proximity Read

NHS-IL12, a Tumor-Targeting ImmunocytokineSemantic proximity Read

Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 ImmunotherapySemantic proximity Read

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read

The Resistance Mechanisms of Checkpoint Inhibitors in Solid TumorsSemantic proximity Read

<i>In situ</i> administration of cytokine combinations induces tumor regressionSemantic proximity Read

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Semantic proximity Read

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responsesSemantic proximity Read

Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination TherapySemantic proximity Read

Novel Immune Drug Combination Induces Tumour Microenvironment Remodelling and Reduces the Dosage of Anti-PD-1 AntibodySemantic proximity Read

Mechanism of resistance to immune checkpoint inhibitorsSemantic proximity Read